Massachusetts Institute of Technology
Program on the Pharmaceutical Industry (POPI)

The Future of the Pharmaceutical Industry Symposium

Pharmacogenomics, Drug Development and the Cost of Healthcare

December 9-10, 2003
Wong Auditorium, Tang Center • MIT Campus

New technologies are shifting the terrain of drug discovery and development. The world of healthcare is undergoing the first part of a major revolution. But will the tremendous advances in science and technology that have unfolded in recent years serve the goal of greater human health? What are the key challenges and issues facing scientists and the pharmaceutical industry? How might the future look?

http://ilp.mit.edu/ilp/Conferences/Current.html
The Future of the Pharmaceutical Industry Symposium
“Pharmacogenomics, Drug Development and the Cost of Healthcare”

The 2003 symposium sponsored by the MIT Program on the Pharmaceutical Industry - “Pharmacogenomics, Drug Development and the Cost of Health Care” - brings together distinguished experts with varying perspectives, including industry, science, government, and academia, to explore this revolution.

The concept of “personalized medicine” – the use of molecular markers to develop drugs targeted to serve the individual patient’s particular condition and side effects profile – will be the framework for the symposium. In three sessions over two days, participants will join in an examination of some of the major advances that are changing the face of pharmaceutical R&D, including SNPs, complex biology, imaging, and tissue engineering. Distinguished experts will discuss what these developments mean for the future of pharmaceutical innovation. A session on disease mechanisms and models will consider the advances in the specific contexts of diabetes, cardiovascular disease, cancer, and infectious diseases, drawing from these examples important lessons that participants will be able to apply to situations in their own work.

Clinical trial design and health economics will be key topics in the session on the Evolving Policy Environment, which will include a panel discussion that brings together the perspectives of consumers, the FDA, healthcare payers, and both large and small firms within the pharmaceutical industry.

This important symposium will be a unique opportunity to gain deep insights into how the industry and society can realize the promise of more effective and better-tolerated therapies, and thus of more efficient use of society’s healthcare resources.

Who Should Attend

This program has been designed for senior executives in organizations affiliated with the pharmaceutical/biotechnology industry, including:

Chief Executive Officers, Presidents, Board Chairmen and Board Members; Executive Vice Presidents; Vice Presidents of Sales and Marketing, Manufacturing, Research and Development, Technology, Finance and Operations; Corporate Counsel; Strategic Planners, and other executives involved with scientific, technical or management issues critical to the long-term health of the industry.

About the MIT Program on the Pharmaceutical Industry

The MIT Program on the Pharmaceutical Industry (POPI) is a unique university-industry-government partnership based at MIT’s Sloan School of Management. It was founded in 1991 to both perform multi-disciplinary research on the factors that drive, constrain and enhance the performance and competitiveness of the pharmaceutical/biotechnology industry, and to educate future scientific and management leaders for the industry and for those organizations that supply it, regulate it or use its products. Among its research and educational accomplishments, POPI continues to contribute activity to areas including drug development, pharmaceutical manufacturing and the pharmaceutical marketplace. It has been supported by more than 30 faculty from MIT Schools of Engineering, Science, and Humanities and Social Science, the MIT-Harvard Division of Health Sciences and Technology and the MIT Sloan School of Management.

To register for this event, visit:
Distinguished Speaker Faculty

Thomas J. Allen, Ph.D., Howard W. Johnson Professor of Management, Professor of Engineering Systems, MacVicar Faculty Fellow & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

Donald C. Anderson, M.D., Senior Vice President & Chief Scientific Officer, Adaptive Therapeutics

Charles L. Cooney, Ph.D., Professor of Chemistry & Biochemical Engineering, Department of Chemical Engineering, Executive Officer & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

William H. Crown, Ph.D., Vice President, Outcomes Research & Econometrics, The MEDSTAT Group, Inc.

George D. Demetri, M.D., Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute

Stan N. Finkelstein, M.D., Senior Research Scientist & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

Irving H. Fox, M.D., C.M., Medical Advisor, Millennium Pharmaceuticals, Inc., & Clinical Professor of Medicine, Harvard Medical School

Geoffrey S. Ginsburg, M.D., Ph.D., Vice President, Molecular and Personalized Medicine, Millennium Pharmaceuticals, Inc.

Martha L. Gray, Ph.D., Edward Hood Taplin Professor of Medical & Electrical Engineering, The Harvard-MIT Division of Health Sciences & Technology, Massachusetts Institute of Technology

Linda G. Griffith, Ph.D., Associate Professor, Division of Biological Engineering, Massachusetts Institute of Technology

David E. Housman, Ph.D., Ludwig Professor of Biology, Center for Cancer Research, Massachusetts Institute of Technology

Kent Larson, Principal Research Scientist & Director, Changing Places, School of Architecture, Massachusetts Institute of Technology

Douglas A. Lauffenburger, Ph.D., Whitaker Professor of Biological Engineering, Biology, and Chemical Engineering & Director, Biological Engineering Division, Massachusetts Institute of Technology

Kip Martha, M.D., Chief Medical & Regulatory Officer, Interleukin Genetics, Inc.

Robert N. McBurney, Ph.D., Chief Scientific Officer & Senior Vice President, Research & Development, Beyond Genomics, Inc.

Alan C. Moses, M.D., Professor of Medicine, Harvard Medical School, Senior Vice-President & Chief Medical Officer, Joslin Diabetes Center, Member of the faculty of Harvard - MIT Health Sciences & Technology

Norman C. Payson, M.D., Former Chairman & CEO, Oxford Health Plans, Inc.

Thomas G. Roberts, Jr., M.D., Instructor in Medicine, Harvard Medical School, Thoracic Oncology Unit, Massachusetts General Hospital, Visiting Scientist, Massachusetts Institute of Technology

Robert H. Rubin, M.D., Gordon & Marjorie Osborne Professor of Health Sciences & Technology, Massachusetts Institute of Technology, & Professor of Medicine, Harvard Medical School

Anthony J. Sinskey, Sc.D., Professor of Microbiology & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

Peter K. Sorger, Ph.D., Associate Professor of Biology and of Biological Engineering, Co-Chair, MIT Computational and Systems Biology Initiative, Massachusetts Institute of Technology

Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research, U.S. Food & Drug Administration
Tuesday, December 9, 2003

Frontiers of Science and Technology

Session Chair: Charles L. Cooney, Ph.D., Professor of Chemistry & Biochemical Engineering, Department of Chemical Engineering, Executive Officer & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

Keynote Address

8:30 The New Biology and the Future of the Pharmaceutical Industry
Anthony J. Sinskey, Sc.D., Professor of Microbiology & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

There is an increased awareness that the number of new chemical entities (NCE) being launched by the pharmaceutical industry has significantly decreased, while R&D expenditures have steadily increased. In addition, a large number of patented pharmaceutical products are going off patent. There is increasing pressure from consumers and insurance companies to reduce healthcare costs. This presentation will review these issues in the context of the new biology in order to answer the questions: Can new biology research and development reverse the trends in the pharmaceutical industry? How will the transition for incorporating new biology approaches into the pharmaceutical sector take place? Is there a need for a paradigm shift in order to improve the quality of the pharmaceutical pipeline? What will be required for the shift to occur?

An important challenge will be how to deal with the business and marketing issues in healthcare during the transition phase to new science approaches for the pharmaceutical industry. Where and how value can be generated by new biology approaches in the pharmaceutical industry will be discussed.

9:25 Pharmacogenomics and Cancer Treatment
David E. Housman, Ph.D., Ludwig Professor of Biology, Center for Cancer Research, Massachusetts Institute of Technology

This talk will address the direct application of pharmacogenomics to cancer treatment. The speaker will consider the impact of pharmacogenomics on current cancer therapies and discuss the interaction between pharmacogenomics and the development of novel therapeutic interventions.

9:55 The Multiple Dimensions of Systems Biology
Douglas A. Lauffenburger, Ph.D., Whitaker Professor of Biological Engineering, Biology, and Chemical Engineering & Director, Biological Engineering Division, Massachusetts Institute of Technology

Biological systems are complex in multiple dimensions, including the number of components considered, the kinds of properties measured for the components, and the level(s) of contextual physiological hierarchy. The Computational & Systems Biology Initiative at MIT seeks to pursue understanding and manipulation across these dimensions in integrated fashion. We will describe example efforts manifesting this integrative perspective, focusing on design and development of molecular therapeutics.

10:25 Applying Systems Biology to Drug Discovery
Peter K. Sorger, Ph.D., Associate Professor of Biology and of Biological Engineering & Co-Chair, MIT Computational and Systems Biology Initiative, Massachusetts Institute of Technology

Systems Biology, as it is being developed at MIT, combines systematic experimentation and computational modeling to describe complex biological networks. As an integrative discipline, systems biology promises to knit together data from diverse sources including genomics, proteomics, target identification and small molecule screening into a Disease Management System. We will discuss this idea with reference to our work on understanding the mechanisms of action of drugs that target EGF receptor signaling. These chemotherapeutics are becoming increasingly important in the clinic but we do not yet understand how to vary their use to optimize treatment strategies.

10:40 Break

10:55 The New Biomedicine: How Emerging Biomedical Technologies Are Changing the Medical Paradigm
Martha L. Gray, Ph.D., Director, Harvard-MIT Division of Health Sciences & Technology (HST), Edward Hood Taplin Professor of Medical & Electrical Engineering, Massachusetts Institute of Technology

For updated program information, visit: http://ilp.mit.edu/ilp/conferences/current.html.

11:25 Talk Title TBA
Linda G. Griffith, Ph.D, Associate Professor, Division of Biological Engineering, Massachusetts Institute of Technology

For updated program information, visit: http://ilp.mit.edu/ilp/conferences/current.html.

11:55 Discussion with Speakers

12:30 - 1:30 Lunch
Impacting Clinical Practice

Session Chair: Robert H. Rubin, M.D., The Gordon & Marjorie Osborne Professor of Health Sciences & Technology, Massachusetts Institute of Technology, Professor of Medicine, Harvard Medical School

1:30 Clinical Applications of Pharmacogenomics: Initial Disease Targets and Early Drivers of Change
Kip Martha, M.D., Chief Medical & Regulatory Officer, Interleukin Genetics, Inc.
The technology for studying the relationships among genetic variation, disease risk and drug response has now matured to the point where its cost, availability, accuracy and reliability are no longer the obstacles preventing its use in clinical medicine. Furthermore, on the surface the integration of pharmacogenomics into our healthcare system has huge potential benefits at several levels from the individual patient to society broadly. So why is it taking so long for it to become a reality?

2:20 Diabetes Mellitus: Technology Implications from Drug Discovery to Patient Application
Alan C. Moses, M.D., Professor of Medicine, Harvard Medical School, Senior Vice-President & Chief Medical Officer, Joslin Diabetes Center, Member of the faculty of Harvard - MIT Health Sciences & Technology
a. The epidemics of diabetes and obesity are interrelated and create both a challenge for effective intervention and an imperative for social action. Technology is beginning to help on the discovery front but not on the health policy side.
b. While the phenotype of diabetes is well understood, the difficulty of identifying specific genetic defects that play a primary role in pathogenesis has hampered drug development and has contributed to the inability to achieve target levels of glucose control in the majority of patients.
c. The impact of diabetes complications on the health of individuals and the cost of healthcare delivery require a renewed effort to target specific biochemical pathways and to refine the molecules that target these pathways. Importantly, technology delivered through point of service diagnostics may be particularly important in creating the rationale for pharmacological intervention to prevent these complications early in the course of disease.
d. Continuous glucose monitoring holds the promise of revolutionizing diabetes care but places some unique burdens on the companies that are developing these technologies from the standpoint of data handling and the presentation to patients of automated clinical recommendations. This area provides a unique example of enabling patient care through technology that will reside directly in the hands of the consumer.

2:55 Personalized Medicine: Changing the Paradigm of Patient Care in Cardiovascular Disease
Geoffrey S. Ginsburg, M.D., Ph.D., Vice President, Molecular and Personalized Medicine, Millennium Pharmaceuticals, Inc.
We are already in the Era of Personalized Medicine in cardiovascular disease. The Personalized Medicine approach has been developed in part out of the need for a more effective strategy in pharmaceutical R&D for developing novel cardiovascular therapeutics. This strategy takes advantage of the genome and allied technologies (expression profiling, proteomics, molecular imaging) that together provide an unprecedented means to probe disease mechanisms and pathways in atherosclerosis, heart failure, and thrombosis and will provide important biomarkers for these diseases as well as for their risk stratification and treatment. Pharmacogenomic biomarkers that predict patient responses to therapies are an imperative in cardiovascular therapies where the treatment benefits are imparted on only a few of the patients treated. Yet, despite the availability already of many such markers, significant challenges exist in the translation of the results of clinical research into clinical practice.

3:25 Break

3:40 The Impact of Molecular and Imaging Technologies on Phase I Cancer Trials
George D. Demetri, M.D., Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute and Thomas G. Roberts, Jr., M.D., Instructor in Medicine, Harvard Medical School, Thoracic Oncology Unit, Massachusetts General Hospital, Visiting Scientist, Massachusetts Institute of Technology
There has been an explosion in the number of molecules under investigation to treat cancer. Despite enormous public and private investment in cancer drug discovery and development, clinical progress remains slow. One of the major efforts underway is to apply correlative science and advanced imaging technologies to evaluate the potential of an agent at its earliest phase of clinical development; the presenters will review the field’s experience with these efforts over the last ten years.

4:30 Discussion with Speakers

To register for this event, visit:
Advancing Technology and the Evolving Health Policy Environment

Session Chair: Thomas J. Allen, Ph.D, Howard W. Johnson Professor of Management, Professor of Engineering Systems, MacVicar Faculty Fellow & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

8:00 Economic and Policy Implications Occasioned by Advancing Science and Technology of Drug Development

Stan N. Finkelstein, M.D., Senior Research Scientist & Co-Director, Program on the Pharmaceutical Industry (POPI), Sloan School of Management, Massachusetts Institute of Technology

Bringing innovative new therapies to market that are based on advancing science and technology of drug discovery and development represents a huge challenge but is only the beginning of the challenge. If these new drugs are to be considered “cost effective,” likely that will result from their being both much more effective, but also more costly. Health care payers are already taking steps to limit access to some of the newest therapies. This presentation will review and comment on how the barriers to accessing drugs based on the “new biology” may affect medical practice and the future of drug development.

8:35 Panel - Industry Perspectives

Systems Biology and the Pharmaceutical Value Chain
Robert N. McBurney, Ph.D., Chief Scientific Officer & Senior Vice President, Research & Development, Beyond Genomics, Inc.

Challenges towards the Implementation of Pharmacogenomics in Mainstream Pharmaceutical Drug Development
Donald C. Anderson, M.D., Senior Vice President & Chief Scientific Officer, Adaptive Therapeutics

The acceptance and successful implementation of pharmacogenomics into major pharmaceutical R&D programs has been impeded by: a) a limited critical mass of human genetics science in the industry, b) a general lack of identified pharmacogenomic markers of use in guiding clinical medicine, c) a poor understanding of commercial strategies to exploit pharmacogenomic data, d) perceived or real risks involved in conducting clinical genetics research, and e) a short sided vision of the ultimate rewards of personalized medicine based on genetic diagnostics.

9:35 Biomarkers to Optimize Clinical Drug Development: Use and Process

Irving H. Fox, M.D., C.M., Medical Advisor, Millennium Pharmaceuticals, Inc., & Clinical Professor of Medicine, Harvard Medical School

Biomarkers are an integral part of the clinical development strategy. They are used when necessary and as they are available to optimize drug development in early and late stage clinical trials. In addition, biomarker discovery research may be performed during clinical trials to optimize the development of the next products or enhance the value of new drugs after approval by improving the benefit-to-risk ratio for patients.

Biomarkers must be planned and developed to meet the needs of clinical drug development and product approval as appropriate. A beneficial way to implement biomarker strategy is to form a biomarker development subteam during the discovery phase of research. This subteam plans and executes biomarker research and coordinates strategy and timelines with the product development project teams.

10:05 Health Economics and Personalized Medicine

William H. Crown, Ph.D., Vice President, Outcomes Research & Econometrics, The MEDSTAT Group, Inc.

For updated program information, visit: http://ilp.mit.edu/ilp/conferences/current.html.

10:35 Will Pharmaceuticals Lose Pricing Power in the United States?

Norman C. Payson, M.D., Former Chairman & CEO, Oxford Health Plans, Inc.

Pharmaceutical companies face two great risk factors in pricing their products in the next decade. First, employers will be offering less first dollar coverage in their employee health benefit plans creating significant consumer price sensitivity. Second, if the government becomes a major buyer of pharmaceuticals for seniors, it may demand favorable pricing. Capacity and pricing power for insurers and healthcare providers has evolved as employer-based financing moved from indemnity to HMO to “managed indemnity” and as governmental payers required progressively more price shifting. Loss of pricing power by big pharmaceuticals will have significant effects on the capital markets and economics of discovery.

10:50 Break

11:05 FDA Policy on Pharmacogenomic Data in Drug Development

Janet Woodcock, M.D., Director, Center for Drug Evaluation & Research, U.S. Food & Drug Administration

This talk will cover the major issues related to the use of pharmacogenomic data during preclinical and clinical drug development, and the resulting regulatory issues.

11:35 Creating Proactive Environments for Healthy Living

Kent Larson, Principal Research Scientist & Director, Changing Places, Massachusetts Institute of Technology

A multi-disciplinary team of researchers from the MIT Changing Places/House_n Consortium is studying how to create pervasive computing environments for the home that promote healthy living. They are developing sensor technologies that can be easily installed in places of living and that can be used to infer information about activities of daily living in non-intrusive, non-stigmatizing ways. They are investigating how environmental sensors and wearable sensors can be used together to create user interfaces that motivate health-related behavior changes, from medication adherence, healthy diet, stress reduction, and increased exercise. Kent Larson will discuss the capabilities of the PlaceLab - a unique residential observational laboratory under construction in Cambridge that will be used to study proactive health technologies for the home.

12:05 Discussion with Speakers

1:00 Close of Event
Registration and Hotel Information

The Future of the Pharmaceutical Industry Symposium
December 9-10, 2003 • Wong Auditorium

To register, please complete the online registration form: http://ilp.mit.edu/ilp/conferences/current.html

For questions regarding registration please contact Diane Vrattos, Conference Coordinator at (617) 253-0414 or vrattos@ilp.mit.edu.

(Note: No Registrations will be taken over the phone.)

Registration Fees

- Early Registration** (on or before October 31, 2003) $1,200
- Full Registration (after October 31, 2003) $1,450
- ILP Members* $ 600

** (Early registration fee is valid only for registrations which are submitted and paid in full on or before 10/31/03. The full registration fee of $1450 will apply to any payment received after 10/31/03, regardless of when registration was submitted.)

Payment Methods

Checks

Please make checks payable to MIT/POPI (payable in US dollars only)

Mail payment to:

MIT Corporate Relations
292 Main Street, E38-500
Cambridge, MA 02139-4307 USA

Attn: Diane Vrattos

Credit Cards

VISA, MasterCard and American Express accepted.

Please provide the following credit card information to Diane Vrattos, Conference Coordinator at (617)253-0414 or vrattos@ilp.mit.edu.

(Visa, MasterCard, Discover or American Express)

Conference attendee’s name:

Amount of charge:

Account number:

Expiration Date:

Cardholder Name:(please print)

Cardholder Signature:

Cancellation Policy: Cancellations received in writing by fax (617-258-0112) or email (register@ilp.mit.edu) before 11/7/03 are entitled to full refund less a $50 processing fee. No refunds will be made after 11/7/03. However, substitutions may be made in writing via e-mail or fax up to 11/7/03. Any substitution after that date should be made at the Conference On-Site Registration Desk.

Accommodations: A block of rooms has been reserved at the Cambridge Marriott near the MIT campus. Please call the hotel directly at 800-228-9290 to arrange accommodations. Rooms are assigned on a first-come, first-served basis, and reservations must be made no later than 11/7/03. Please refer to The MIT POPI Conference to receive the $169 room rate, plus local tax, single or double occupancy.

Please Register Me for the December 9-10, 2003 MIT Symposium on The Future of the Pharmaceutical Industry

Name

Title

Organization

Department

Address

City

State

Zip

Phone

Fax

E-mail

Team Registration

Others attending with me include:

Name, Title

Name, Title

(Please note if the addresses of team differ)

To register online, go to: http://knowledgebase.mit.edu/ilp/conferences/conf-handler.taf?ConfCode=POPI03

- I/we belong to an ILP member company (registration fee $600)
- I/we do not belong to an ILP member company, before 10/31/03 ($1200)
- I/we do not belong to an ILP member company, after 10/31/03 ($1450)
- I/we are MIT alumni/ae ($725)
- I/we are POPI Sponsors (No Charge)
- I/we are members of the MIT Community (No Charge)
- Check enclosed. (Please make payable to MIT/POPI). U.S. Dollars only.
- Please bill me. Payment is required prior to session.
- I can not attend the program on the date listed, but would like to be notified of future executive programs offered by the MIT Program on the Pharmaceutical Industry.
Program on the Pharmaceutical Industry (POPI)

The Future of the Pharmaceutical Industry Symposium

Pharmacogenomics, Drug Development and the Cost of Healthcare

Massachusetts Institute of Technology
Program on the Pharmaceutical Industry (POPI)

The Future of the Pharmaceutical Industry Symposium

Pharmacogenomics, Drug Development and the Cost of Healthcare

December 9-10, 2003
Wong Auditorium, Tang Center • MIT Campus

http://ilp.mit.edu/ilp/Conferences/Current.html